Healthcare Venture Capital Report - 2019 NEW YORK CIT Y
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
NE W YORK CIT Y
Healthcare Venture
Capital Report
2019
INTRODUCTION
Welcome to the second annual
New York City Healthcare
Venture Capital Report.
For 2019, we have expanded the scope of our report
by including insights and expertise from 15 of NYC’s
leading investors and entrepreneurs, and for the first
time, have added a ranking of the top 25 funded health
companies and highlighted NYC’s leading healthcare
investors to know.
Thanks to all who contributed to this report, and a Healthcare is vital to NYC’s economy in many ways
special acknowledgement to our partners at Cooley, including as a major employer. Of the largest NYC
who helped gather all of the data for this report, as employers listed in Crain’s New York 2018 list, 30%
well as our quarterly updates throughout the year. come from our health systems (Northwell, NYC Health
and Hospitals, Mount Sinai, Montefiore, NYU Langone
2018 was a remarkable year for healthcare investing in and NewYork-Presbyterian) representing 217,000 jobs.
the United States reaching an all-time high of $30+
billion across multiple sectors (PitchBook-NVCA Venture As Ellie Wheeler, partner at Greycroft, points out: “There is
Monitor, December 2018). New York was no different and a vibrant and ever-expanding ecosystem here in New York
experienced impressive growth – we saw $1.85 billion City, including access to pharmaceutical companies and
invested across 83 healthcare companies. Like the rest big insurers, not to mention a significant percentage of
of the industry, we saw larger rounds at all stages. Fortune 500 companies and other big employers that all
have increasing incentives to get involved in healthcare.
Importantly, we saw several critical exits. Roche’s With major universities here as well, there is a significant
acquisition of Flatiron Health for $2.1 billion last February amount of talent and it is only getting better.”
was a watershed moment for NYC health start-ups.
Ezra Mehlman, Managing Partner of Health Enterprise The New York healthcare market continues to flourish.
Partners, commented: “We may just be hitting the apex We’re excited to see what the coming year has in store
moment of healthcare venture capital investing: with for NYC.
fundraising levels and valuations at all-time highs, the
only viable exit for many companies is an IPO or In good health,
multi-billion dollar acquisitions.”
While Flatiron garnered the lion’s share of attention, NYC
had other important exits. Syntimmune, founded in 2013
by Dr. Laurence Blumberg, a serial biopharma entrepreneur,
Bunny Ellerin
and his brother Dr. Richard Blumberg, was acquired by
President
Alexion for $400 million. WebMD (which was acquired by
New York City Health Business Leaders
NYC-based IAC) also added two local healthcare properties
to its platform – Vitals and Jobson Healthcare.
2
2018 BY THE NUMBERS
83 $1.85B
HEALTH
COMPANIES IN FUNDING
RECEIVED IN 2018
3%
OTHER
($58M)
31%
HEALTH INSURANCE
10% ($574M)
DATA ANALYTICS
26%
($177M)
FUNDING BY
13% SECTOR BIOPHARMA
($488M)
PATIENT ENGAGEMENT
($232M)
17%
CONSUMER HEALTH
($320M)
7%
SEED/ANGEL
27%
($129M)
SERIES A
($508.5M)
FUNDING BY 16%
ROUND
VENTURE BOUND
($289M)
27%
LATE STAGE*
23%
SERIES B
($503.5M) ($419M)
* Series C/D/Corporate
3
TOP 25 FUNDED NYC
# Company Description Sector $ Raised Key Investors
(MM)
Health insurance company employing
Health Alphabet, Founders Fund,
1 technology, design, and data to $540
Insurance CapitalG, Verily
humanize healthcare.
Direct-to-consumer healthcare
FirstMark Capital, SignalFire,
company handling everything from Consumer
2 $88 Initialized Capital, General
online diagnosis to convenient Health
Catalyst
delivery of medication.
Lux Capital, The Column Group,
Biotechnology company developing a Polaris Partners, Euclidean
3 BioPharma $87
platform to harness the gut-brain axis. Capital, Two Sigma Ventures,
Alexandria Ventures, Bill Gates
Biotechnology company developing
disease-modifying gene therapies
4 BioPharma $75 Orbimed
for Parkinson’s disease and other
neurodegenerative disorders.
Biotechnology company developing
Versant Ventures, Forbion, S.R.
5 a novel drug class targeting BioPharma $54
One, Alexandria Ventures
RNA-modifying proteins.
Technology company rebuilding
the pharmacy industry that enables Consumer Thrive Capital, Brook Capital
6 $50
customized outcomes for doctors, Health Partners
hospitals, insurers, and manufacturers.
Biotechnology company
commercializing pharmaceuticals
6 BioPharma $50 C-Bridge Capital
for patients in Emerging Markets
including Asia Pacific.
Biotechnology company pursuing Versant Ventures, Polaris
8 next-generation immuno-oncology BioPharma $48 Partners, LS Polaris Innovation
research and drug development. Fund
Medical technology company applying
9 artificial intelligence to improve clinical Data Analytics $40 GV, DFJ, Zach Weinberg
diagnostics.
Real-world data and analytics
company using proprietary IQVIA, EW Healthcare Partners,
9 Data Analytics $40
methodology to enable precision Memorial Sloan Kettering
medicine at scale.
Healthcare technology company F-Prime, Polaris Partners, Oak
Patient
9 improving behavioral health delivery $40 HC/FT, GV, Deerfield
Engagement
for patients, providers, and payers. Management
Novo Holdings A/S, Sofinnova
Discovery platform revolutionizing
Partners, Lepu Medical,
9 cancer treatment through first-in-class BioPharma $40
Alexandria Ventures,
therapeutics.
Partnership Fund NYC
4
HEALTH COMPANIES IN 2018
# Company Description Sector $ Raised Key Investors
(MM)
AI-powered health application for
Consumer 14W, Comcast Ventures,
13 consumer health education and $37.5
Health Mangrove Capital Partners
linkage to primary care.
Healthcare technology company that
New Enterprise Associates, Flare
delivers real-world evidence for life
14 Data Analytics $36.4 Capital Partners, Lakestar, Town
sciences companies, payers, and
Hall Ventures
providers.
Patient payment and engagement Kinnevik, Founders Fund, Thrive
Patient
15 platform for hospitals, health systems $36 Capital, Lakestar, Sound
Engagement
and medical groups. Ventures
New type of health plan aligning
Bain Capital Ventures, F-Prime,
employers, employees, and Health
16 $34 Maverick Ventures, Bessemer,
providers to ahieve cost-effective, Insurance
Ingleside Investor
high-quality care.
Biotechnology company treating
Abbvie Ventures, Alexandria
neurodegeneration and neuronal
17 BioPharma $31 Ventures , ARCH, Pfizer
injuries through development of
Ventures
novel therapeutics.
Goldman Sachs Investment
Subscription-based personalized Consumer Partners, Goodwater Capital,
18 $29
vitamin packs. Health Juxtapose, RRE Ventures, Tusk
Ventures
Sequoia, Oak HC/FT, Spring
Virtual clinic dedicated to women’s Consumer
19 $27 Mountain Capital, 14W, Female
and family health. Health
Founders Fund
Healthcare technology company
transforming cancer diagnosis,
20 Data Analytics $25 Breyer Capital
treatment and prevention through
cutting-edge AI.
Episode-based digital care delivery Patient
21 $21 Insight Venture Partners
and remote patient monitoring. Engagement
Designing personalized health system
Maverick Ventures, Thrive
for qualifying Medicaid and Medicare Patient
22 $20.8 Capital, Sidewalk Labs, Oxeon,
beneficiaries living in underserved city Engagement
Town Hall Ventures
neighborhoods.
Behavioral healthcare company in Behavioral
23 $20 F-Prime Capital Partners
psychiatric hospital space. Health
Diabetes management platform
Patient
24 that harnesses the power of mobile $17.4 Innova Capital Partners, FJ Labs
Engagement
computing and data science.
Healthcare technology company
developing and commercializing Digital
25 $17 Sanofi Ventures
software as prescription medical Therapeutics
treatments.
QA & WITH NYC’S TOP
MOVERS & SHAKERS
Todd Pietri | Managing Partner, Aran Ron | Partner, FundRx
Activate Venture Partners The city has developed an ecosystem of individuals
New York has robust technology and healthcare who are really interested in early-stage companies.
sectors. What makes New York different is that you As a result, New York is attracting a lot of young,
have the life sciences and pharmaceutical corridor, high-energy, smart people with great ideas who
which is a big plus and difficult to replicate. There want to start early-stage companies. New York City
are multiple generations of good companies that has become the ideal environment and may even
have grown up here. be better than, or at least rival, Silicon Valley.
Ellie Wheeler Q: What are the benefits of
Partner, Greycroft
Our firm is in both New
being an investor in NYC?
York and Los Angeles,
and to date, our
healthcare investing has
been led out of the New
York office. It is not just
out of interest of our
investing partners, but Drew Schiff | Managing Partner, Aisling Capital
because New York is For life science ventures, NYC provides access to and consultation with not
where we are seeing the only an expert but potentially many experts that are only a subway ride away.
companies located and From NewYork–Presbyterian, Rockefeller and Memorial Sloan Kettering up
where we are seeing the to Montefiore/Einstein back through Columbia and Mt. Sinai and then down
most opportunity. to NYU and out to Brooklyn, there are clinicians and researchers that can
provide relevant and important perspective and advice.
Ezra Mehlman | General Partner, Health Enterprise Partners
NYC has many of the essential building blocks for a vibrant healthcare venture system. The presence of: several large
health systems with well-resourced investment and innovation programs; a deep pool of intellectual talent emerging
from graduate schools; an accumulation of NYC-based “alumni” from large tech companies who possess dedicated
healthcare interests; the proliferation of venture accelerators; and of course a general abundance of financial capital
have created a unique healthcare entrepreneurial environment in New York.
6
Florian Otto | CEO, Cedar
New York is a hot bed for entrepreneurship - there’s an incredible energy
here that I’ve grown to love. The city has so many resources that, when
utilized correctly, can really help put you on a path towards success. We Carolyn Magill
believe that the engineering talent in NYC is on par with (or perhaps even CEO, Aetion
beginning to surpass) Silicon Valley.
New York City has been
an ideal location for us
due to the volume of
expertise within the
region, across all sectors
of healthcare. Not only is
the talent pool diverse
Q: What are the and full of people who
are passionate about
improving healthcare,
Zachariah Reitano
Co-founder and CEO, Ro
benefits of being we’re close to many of
our current (and potential)
partners—from biopharma
From hospitals to medical
schools to pharmaceutical
an entrepreneur to payers and providers,
which enables us to build
companies, New York City is
home to many of the most
in NYC? collaborative relationships
between them.
renowned healthcare
institutions in the world. This
has enabled Ro to benefit
from the unparalleled wealth
of knowledge of international
thought leaders and to Jean Drouin | CEO, Clarify Health
garner the enthusiastic New York’s strength in a broad range of tech fields—from health
support of medical experts and advertising and finance to digital media and ecommerce—
in every field through each makes it an ideal place for Clarify to plant roots and grow. We’re
phase of our growth. thrilled to be part of the constantly evolving New York City tech
scene, where we can easily network and exchange learnings with
other companies in the community.
Wendy Goldstein and Yvan-Claude Pierre | Partners, Cooley
Being home to large pharma companies and many life sciences companies makes it a very active, robust and also
mature ecosystem, as well as burgeoning market for innovative technologies. In addition, given NYC’s proximity to
New Jersey which ranks second in cancer treatment drugs in development, the NYC/New Jersey corridor is the
leading differentiated region in the healthcare/life sciences industry.
7
NYC TOP HEALTHCARE
H E A LT H C A R E S P E C I F I C I N V E S TO R S
Investor Sector Notable NYC Investments
Intercept Pharmaceuticals, Synergy
Aisling Capital
Pharmaceuticals, Loxo Oncology, Bioenvision
Apple Tree Partners Syntimmune
Casdin Capital Flatiron Health, Clover Health
Cureatr, Quartet, Sermo, Schrodinger,
Deerfield Management
Intra-Cellular Therapies
Digitalis CareDox, Somatix
FundRx Annum Health, EpiBone, Epicured, Wellth
Health Catalyst Capital
Risalto Health
Management
Health Enterprise Partners Vitals
LifeSci Venture Partners Attune Pharmaceuticals, Rocket Pharma
AiCure, Truveris, NY Digital Health Accelerator,
New Leaf Venture Partners
Intercept Pharmaceuticals
NewYork-Presbyterian
WorkFusion
Ventures
NGN Capital Exosome Diagnostics, Vivaldi Biosciences
Prevail Therapeutics, Intercept Pharmaceuticals,
OrbiMed Adicet Bio, Loxo Oncology, SmartZyme
BioPharma
Aetion, Centivo, Pager, Quartet, Risalto Health,
Oxeon Partners
RubiconMD
Magnolia Neurosciences, Petra Pharma,
Pfizer Venture Investments
Accelerator Corporation, Lodo Therapeutics
RTW Investments Roivant Sciences, Rocket Pharma
StartUp Health CareDox, Cohero Health, Doctor.com, Zeel
Windham Venture Partners Cureatr, Credsimple, Novocure, Blueprint Health
INVESTORS TO KNOW
G E N E R A L I N V E S TO R S
Investor Sector Notable NYC Investments
Activate Venture Partners Cureatr, Healthify, Medidata, Vitals
Alma, K Health, Ro, Oscar Health,
BoxGroup
FlatIron Health
Collaborative Fund Zipdrug, Sherpaa
BioDigital, Parsley Health, Phosphorous
FirstMark Capital
Diagnostics, Ro
Cylera, Call9, Maven Health, Flatiron
Great Oaks Venture Capital
Health
Eden Health, Health Reveal, Thrive
Greycroft
Global
K Health, Maxwell Health, Oscar, Thrive
Lerer Hippeau Ventures
Global, Talkspace
Kallyope, Zipdrug, Hometeam, Pager,
Lux Capital
SOLS
Cureatr, Petra Pharma, Spring Health,
Partnership for New York City
Wellth
RRE Ventures Care/Of, Nomad Health, Spring Health
Capsule, Cedar Health, Cityblock
Thrive Capital
Health, Oscar Health
SECTOR LEGEND
BioPharma Health Technology Health Services
Medical Devices &
Diagnostics & Tools
Supplies
9
Q: How has Gil Addo
CEO, RubiconMD
the NYC venture The tech ecosystem
in NYC has been
community Michael Aberman | CEO,
incredibly supportive
of us. The community
supported Quentis Therapeutics has put tremendous
resources behind
The NYC venture community has been
your growth? very supportive. NY State participated in
our Series A, NYC provided investment to
health tech
innovation. That is
why we moved from
fund our NYC headquarters and
Boston to NYC to
Versant’s NY investment arm – Highline
start this business.
Therapeutics – funded our Series A. Plus
Over the last 5+
our technology is licensed from Cornell!
years, we’ve seen
the community as
both incredibly
collaborative and
Bronwyn Spira | CEO, Force Therapeutics helpful in supporting
and promoting us.
StartUp Health has been helpful in creating a community of Healthcare
thought leaders. The academic community has supported recruiting
efforts, especially places like Columbia’s MPH program, Flatiron School
and General Assembly.
Joel Wishkovsky | CEO, Simple Contacts
New York State has kept an open dialogue with us. They have been very pro-innovation.
Through our relationships with the academic community, we get to work with leading Drew Schiff
experts in the medical field and see the latest tech coming out of the universities. Managing Partner,
Aisling Capital
Recruiting early-stage
researchers, drug
developers and life
science innovators
to a city with high
Ezra Mehlman
General Partner, Health
Q: What are some operating costs and
a high cost of living
is almost always a
Enterprise Partners of the challenges of consideration that
needs to be thought
building a business
Despite making major through not only at
strides towards providing the initial stages but
subsidized office space as a company gains
and resources for startups
in the city, NYC remains a
in NYC? traction and grows of
several employees to
very expensive place to live dozens or hundreds
and work. of employees.
10Aran Ron | Partner, FundRx Florian Otto
There are enormous inefficiencies in the CEO, Cedar
healthcare system, and we’ve only scratched the
There is no denying that there is a
surface of addressing those inefficiencies. I’m
consumerization trend taking over healthcare.
optimistic about companies that can provide
Health insurance is an area that can be much
better services or IT solutions that can capture
more patient friendly. Understanding patient
data in a different way.
benefits should be easier and insurers could
be a more active partner in how patients
consume healthcare.
Bronwyn Spira | CEO,
Q: Which healthcare sectors
Force Therapeutics
Patient engagement
are you excited about?
and patient enablement
platforms will be key to
managing costs and
enhancing the patient
experience in healthcare.
Wendy Goldstein | Yvan-Claude Pierre
Partners, Cooley
We are most excited about gene therapy and gene editing as
healthcare subsectors grow in the next 5 years and beyond. The
possibilities of gene therapy and gene editing hold much promise
Ellie Wheeler
and with careful planning and regulation, gene therapy and gene
Partner, Greycroft editing will become an important remedy of the near future.
We’re excited about
anything that is bringing
transparency to
healthcare. We’re also
excited about analytics
that are driving better
Todd Pietri | Managing Partner, Activate Venture Partners
outcomes and cost
efficiencies, and the We’re interested in Health Economics & Outcomes Research (HEOR).
startups addressing the We’re also interested in end of life or palliative care and innovation around
changing landscape of primary care business models that will have less brick and mortar, and more
care, including on-site, telemedicine and virtual care.
near-site, and
telemedicine. It will be
important to approach
it with a consumer lens.
11WHAT TO WATCH FOR
IN 2019
2019 is shaping up to be a pivotal year for
New York healthcare. We predict the following
trends in the year ahead:
1. 2. 3.
DTC Health will Biotech will hit its stride. Healthcare delivery
continue to flourish. When will NYC catch up to Boston will surprise you.
Direct-to-consumer services like and SF? We’re starting to see First came One Medical. Then
Ro, Capsule, Simple Contacts and traction. In 2018, $488 million went CityMD. And we realized that the
Parachute Health are booming. to local biotech startups like days of the sterile physician office,
They offer so much of what Kallyope, Prevail Therapeutics, long wait times, and inability to
traditional healthcare doesn’t – Gotham Therapeutics, Quentis connect by anything but phone
personalization, ease of use, Therapeutics and Rgenix. Lab were numbered. Now we have
seamless customer experience space, once a huge gap, is coming telehealth, in-home visits, concierge
and privacy when it matters. online with the expansion of the service - all tech-enabled. Think
They also connect directly with West Side’s Hudson Research Maven, Eden Health, Parsley
providers and health plans to Center (home to NY Stem Cell Health, Alma, and Heartbeat
alleviate customer stress. Foundation) and Alexandria’s Health. No doubt we’ll see more
Expect the trend continue. planned third tower on the East models emerge in 2019.
Side. JLABS @ NYC opened in
June inside the New York Genome
Center and ELabNYC announced its
7th cohort in December. The life
science vision is finally taking shape.
124. 5. 6.
Patient engagement Data that informs will New models will disrupt
will simplify and transform the market. the PBM industry.
improve care. The holy grail is actionable data Will 2019 be the year that PBMs
that drives better decision-making, are disrupted? We think so. Lack
Navigating healthcare can be hard.
changes behavior, leads to better of transparency and misaligned
Tools that help patients simplify
outcomes. As payment models incentives may be coming to an
the complexities of access,
shift from volume to value and end. We’ve had discussions with
adherence, benefits and payments
clinical decisions become more multiple startups looking to break
help them take back some control.
complex, key stakeholders need the PBM hold on pricing and
NYC is home to companies in all
advanced analytics to help them distribution. We expect to see
categories - Cedar, Force
thrive. Medidata was one of the one or more funded in 2019.
Therapeutics, AbleTo, Cecilia
first to recognize this, followed by
Health and Wellthie to name a
Crossix, Prognos, Flatiron and
few. These services address real
others. Today startups like Aetion,
gaps for patients and families
Cota and Clarify Health are leading
which will lead employers and
the way to better outcomes.
plans to cover them, driving
Paige
growth in this category.
Wa t son
“
HELLO my name is...
Since Oscar launched in NYC in late health strategy and analytics at It supports the
2012, we’ve noticed a growing trend. RedPeak, to weigh in. “The most
It showed up several times during successful health tech companies idea that some
2018 with the launch of Eden have recognized that they need to technologies should
Health, Paige.AI, Alma and Ezra.AI. appeal to the human in all of us.
It was cemented during JP Morgan Using a name like Watson or Paige be considered a
when Fit4D announced its name is one way to humanize technology. partner or ally
change to Cecilia Health. What’s the It supports the idea that some
deal with first names as company technologies should be considered to care teams
names? We asked branding expert
John Breen, executive director of
a partner or ally to care teams
going forward.”
going forward.”
13Carolyn Magill | CEO, Aetion
Always keep in mind the mission of healthcare and how your product
or service improves the experience of delivering and receiving care.
Most importantly, make sure you are building a business you’re truly Michael Aberman
passionate about, and stay focused on solving real unmet needs. CEO, Quentis
Therapeutics
Some of the challenges
associated with NYC are
diminishing. We used to
Zachariah Reitano | Co-founder and CEO, Ro be a smaller biotech
community than other
Don’t be intimidated by regulation. Healthcare is complex
“hubs” but this is changing
and this complexity isn’t going anywhere any time soon.
rapidly. On the real estate
However, this is an opportunity for startups. Own the
front, there was not much
complexity for patients. Make their lives more simple by
developed lab space. This
making your life more difficult.
has improved greatly and
may not be as much of an
issue now.
MOVERS & SHAKERS
FINAL THOUGHTS
Jean Drouin | CEO, Clarify Health
We continue to be humbled by the depth of talent in
Gil Addo the city and inspired by the creativity, vitality and special
CEO, RubiconMD capacity of New Yorkers to get things done.
The capital,
customers and
collaborators you
need to grow are
all in and around
NYC. Hop on the
subway or train
Joel Wishkovsky | CEO, Simple Contacts
and go to them. Stay focused. Don’t get distracted by all the opportunities around you. Focus
instead on what you are here to build.
14METHODOLOGY AUTHORS
Data used in the creation of this report
was obtained from PitchBook and covered
the period from 01/01/2018 to 12/31/2018.
PitchBook places companies into various
healthcare subsectors, which we reviewed
and used in our analysis. These include:
Zack Caplan is an MBA
• Healthcare Devices and Supplies Bunny Ellerin is president student at Columbia
• Healthcare Services and co-founder of NYC Business School. Zack’s
Health Business Leaders. professional experience
• Healthcare Technology Systems
She is also Director of includes healthcare
• Pharmaceuticals and Biotechnology the Healthcare and technology startup Stellar
• Other Healthcare Pharmaceutical Management Health, Boston Children’s
Program at Columbia Hospital’s Innovation and
Company Analysis: Business School. Bunny Digital Health Accelerator,
We included a company on the list if (1) is passionate about driving and Deloitte Consulting’s
the company was classified in a healthcare change and transforming healthcare strategy and
category above in the PitchBook database; healthcare. operations practice.
(2) the company listed NYC as its
corporate headquarters; (3) the company
received seed, angel, early-stage or
late-stage funding during the period
01/01/2018 to 12/31/2018.
Investor Analysis: ACKNOWLEDGEMENTS
To compile a list of New York City
healthcare venture capitalists, we used the One of the factors that differentiates NYC from other markets
PitchBook database to identify investors is the entrepreneurs, investors and advisors who are driving
within New York City who had done at least innovation within our health ecosystem. Thank you to our
one healthcare deal during the period esteemed contributors for providing insights for this report.
01/01/2018 to 12/31/2018. Only seed, Gil Addo | CEO, RubiconMD
angel, early-stage and late-stage were
considered. We considered an investor to Michael Aberman, MD | CEO, Quentis Therapeutics
be in New York City if the fund listed New Jean Drouin, MD | CEO, Clarify Health
York City as its headquarters OR if the
Wendy Goldstein, Esq. | Partner, Cooley
fund had a dedicated office in New York
City. The analysis is centered on VC-focused Carolyn Magill | CEO, Aetion
investors, however private equity investors Ezra Mehlman | General Partner, Health Enterprise Partners
with VC deals in the healthcare sector also
Florian Otto, MD | CEO, Cedar
were considered.
Yvan-Claude Pierre, Esq. | Partner, Cooley
Disclaimer
This report is provided for informational Todd Pietri | Managing Partner, Activate Venture Partners
purposes only. Where possible, we verified Zachariah Reitano | Co-founder and CEO, Ro
information obtained from PitchBook
Aran Ron, MD | Partner, FundRx
through publicly-available sources (e.g.
company press releases, news reports) Drew Schiff, MD | Managing Partner, Aisling Capital
and made judgment calls based on that. Bronwyn Spira, PT | CEO, Force Therapeutics
If you find an error in the report, please
Ellie Wheeler | Partner, Greycroft
contact us at info@nychbl.com so that we
can correct it. Joel Wishkovsky | CEO, Simple Contacts
15NYC Health Business Leaders is a
professional community of 3,000 senior
executives who are leading, innovating
and driving healthcare forward.
For more information visit
www.nychbl.com or follow us @nychbl.
Thank you to the Cooley team
for their support and partnership!
16You can also read
